Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's disease.

ABSTRACT:

Aims

A strategy based on therapeutic drug monitoring and population pharmacokinetic (popPK) models would likely increase the rate of clinical remission (CR) after infliximab (IFX) induction in patients with Crohn's disease (CD). This study aimed to evaluate the relationship between early IFX levels and antibodies to infliximab (ATI) and CR at week 14 and simulate the probability of attaining the identified exposure target.

Methods

Patients with CD (n = 140) treated with IFX were enrolled to develop the popPK model. Of these, 43 moderate-to-severe patients with CD were followed up at week 14. Simulations were performed on patients with different dosage regimens and covariates.

Results

IFX levels >20.08 μg/mL at week 2, >18.44 μg/mL at week 6, and >3.08 μg/mL at week 14

SUBMITTER: Zhu K 

PROVIDER: S-EPMC11384982 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature